Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7613556rdf:typepubmed:Citationlld:pubmed
pubmed-article:7613556lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:7613556lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:7613556lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:7613556lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:7613556lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:7613556lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:7613556lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:7613556pubmed:issue1lld:pubmed
pubmed-article:7613556pubmed:dateCreated1995-8-23lld:pubmed
pubmed-article:7613556pubmed:abstractTextA critical aspect of biomedical research is the characterization of the dose response relationship of a compound. This is true in laboratory experiments and clinical trials and pertains to efficacy, safety, and the resulting benefit/risk ratio. Presented here is Part I of this article, which deals with some clinical trial design issues surrounding dose response studies. Some additional comments are made about trials for identifying the minimum effective dose, randomized concentration controlled trials, and the use of one-sided hypotheses in designing such trials. Part II is a separate paper reviewing some analysis strategies for dose response studies.lld:pubmed
pubmed-article:7613556pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7613556pubmed:languageenglld:pubmed
pubmed-article:7613556pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7613556pubmed:citationSubsetIMlld:pubmed
pubmed-article:7613556pubmed:statusMEDLINElld:pubmed
pubmed-article:7613556pubmed:monthMarlld:pubmed
pubmed-article:7613556pubmed:issn1054-3406lld:pubmed
pubmed-article:7613556pubmed:authorpubmed-author:RubergS JSJlld:pubmed
pubmed-article:7613556pubmed:issnTypePrintlld:pubmed
pubmed-article:7613556pubmed:volume5lld:pubmed
pubmed-article:7613556pubmed:ownerNLMlld:pubmed
pubmed-article:7613556pubmed:authorsCompleteYlld:pubmed
pubmed-article:7613556pubmed:pagination1-14lld:pubmed
pubmed-article:7613556pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:7613556pubmed:meshHeadingpubmed-meshheading:7613556-...lld:pubmed
pubmed-article:7613556pubmed:meshHeadingpubmed-meshheading:7613556-...lld:pubmed
pubmed-article:7613556pubmed:meshHeadingpubmed-meshheading:7613556-...lld:pubmed
pubmed-article:7613556pubmed:meshHeadingpubmed-meshheading:7613556-...lld:pubmed
pubmed-article:7613556pubmed:meshHeadingpubmed-meshheading:7613556-...lld:pubmed
pubmed-article:7613556pubmed:meshHeadingpubmed-meshheading:7613556-...lld:pubmed
pubmed-article:7613556pubmed:year1995lld:pubmed
pubmed-article:7613556pubmed:articleTitleDose response studies. I. Some design considerations.lld:pubmed
pubmed-article:7613556pubmed:affiliationMarion Merrell Dow Inc., Kansas City, Missouri 64134-0627, USA.lld:pubmed
pubmed-article:7613556pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7613556pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7613556lld:pubmed